title: Dopamine inhibits cytokine release and expression of tyrosine kinases, Lck and Fyn in activated T cells.
abstract: The effect of dopamine (DA) on the release of cytokines from activated human T cells has been evaluated to analyze the mechanism by which physiological concentration of dopamine inhibits T cell proliferation. Dopamine inhibited anti-CD3 mAb-induced release of both Th1 and Th2 cytokines, IL2, IFN-gamma and IL4 from T cells by specific class of dopamine receptors. This action of dopamine was mediated by a new mechanism. Dopamine suppressed non-receptor tyrosine kinases, Lck and Fyn expression which are the initial and pivotal signaling steps in T cell receptor (TCR) mediated different down stream signaling cascades, leading to cytokine release and subsequent clonal expansion of these immune effector cells.
authors.affiliation: Signal Transduction and Biogenic Amines Laboratory, Chittaranjan National Cancer Institute, Research Building, 37, SP Mukherjee Road, Calcutta 700026, India.
authors.forename: Manik Chandra
authors.initials: MC
authors.lastname: Ghosh
authors.forename: Amal Chandra
authors.initials: AC
authors.lastname: Mondal
authors.forename: Sujit
authors.initials: S
authors.lastname: Basu
authors.forename: Samir
authors.initials: S
authors.lastname: Banerjee
authors.forename: Jahar
authors.initials: J
authors.lastname: Majumder
authors.forename: Debasis
authors.initials: D
authors.lastname: Bhattacharya
authors.forename: Partha Sarathi
authors.initials: PS
authors.lastname: Dasgupta
mesh_terms: D000328:Adult; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D004298:Dopamine / Q000494:pharmacology* / Q000502:physiology; D005260:Female; D006801:Humans; D015151:Immunoblotting; D066298:In Vitro Techniques; D007371:Interferon-gamma / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D007376:Interleukin-2 / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D015847:Interleukin-4 / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D008213:Lymphocyte Activation; D019860:Lymphocyte Specific Protein Tyrosine Kinase p56(lck) / Q000037:antagonists & inhibitors* / Q000235:genetics; D008297:Male; D011233:Precipitin Tests; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics; D051076:Proto-Oncogene Proteins c-fyn; D017448:Receptors, Dopamine D2 / Q000096:biosynthesis / Q000235:genetics; D050637:Receptors, Dopamine D3; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013601:T-Lymphocytes / Q000187:drug effects* / Q000378:metabolism; D018417:Th1 Cells / Q000378:metabolism; D018418:Th2 Cells / Q000378:metabolism
chemical_list: D016207:Cytokines; C493593:DRD3 protein, human; D007376:Interleukin-2; D011518:Proto-Oncogene Proteins; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D015847:Interleukin-4; D007371:Interferon-gamma; C494957:FYN protein, human; D019860:Lymphocyte Specific Protein Tyrosine Kinase p56(lck); D051076:Proto-Oncogene Proteins c-fyn; D004298:Dopamine